EOLS – Evolent Health Inc.
EOLS
$7.42Name : Evolus, Inc. Common Stock
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $491,117,696.00
EPSttm : -0.48
Evolus, Inc. Common Stock
$7.42
EOLS — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
10.39
Margin Of Safety %
Put/Call OI Ratio
0.01
EPS Next Q Diff
0.16
EPS Last/This Y
0.75
EPS This/Next Y
0.34
Price
7.43
Target Price
15.4
Analyst Recom
1.33
Performance Q
-7.48
Upside
-321.7%
Beta
1.35
Ticker: EOLS
22 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-13 | EOLS | 7.49 | 0.02 | 0.66 | 17648 |
| 2026-10-14 | EOLS | 7.22 | 0.02 | 0.15 | 17647 |
| 2026-10-15 | EOLS | 7.57 | 0.02 | 0.07 | 17656 |
| 2026-10-16 | EOLS | 7.14 | 0.02 | 0.00 | 17651 |
| 2026-10-19 | EOLS | 7.36 | 0.01 | 5.43 | 16917 |
| 2026-10-20 | EOLS | 7.36 | 0.01 | 0.00 | 16999 |
| 2026-10-21 | EOLS | 7.41 | 0.01 | 0.00 | 17011 |
| 2026-10-22 | EOLS | 7.4 | 0.01 | 0.62 | 17013 |
| 2026-10-23 | EOLS | 7 | 0.01 | 0.20 | 17003 |
| 2026-10-26 | EOLS | 7.13 | 0.01 | 0.00 | 16991 |
| 2026-10-27 | EOLS | 7.36 | 0.01 | 0.00 | 16992 |
| 2026-10-28 | EOLS | 7.64 | 0.01 | 0.00 | 15993 |
| 2026-10-29 | EOLS | 7.5 | 0.01 | 0.00 | 15796 |
| 2026-10-30 | EOLS | 7.34 | 0.01 | 0.01 | 15806 |
| 2026-11-02 | EOLS | 7.16 | 0.01 | 0.91 | 15348 |
| 2026-11-03 | EOLS | 7.39 | 0.01 | 0.00 | 15368 |
| 2026-11-04 | EOLS | 7.46 | 0.01 | 0.00 | 15640 |
| 2026-11-05 | EOLS | 6.8 | 0.01 | 0.15 | 15691 |
| 2026-11-06 | EOLS | 6.8 | 0.01 | 0.00 | 15687 |
| 2026-11-09 | EOLS | 6.97 | 0.01 | 0.00 | 15692 |
| 2026-11-10 | EOLS | 6.8 | 0.01 | 0.00 | 15703 |
| 2026-11-11 | EOLS | 7.43 | 0.01 | 0.00 | 15725 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
22 items
«
‹
Current Page1 of 1
›
»
22 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-13 | EOLS | 7.51 | 59.4 | 30.5 | -0.05 |
| 2026-10-14 | EOLS | 7.22 | 59.4 | 30.5 | -0.05 |
| 2026-10-15 | EOLS | 7.58 | 59.4 | 31.0 | -0.05 |
| 2026-10-16 | EOLS | 7.09 | 54.3 | 30.2 | -0.05 |
| 2026-10-19 | EOLS | 7.36 | 54.3 | 31.3 | -0.05 |
| 2026-10-20 | EOLS | 7.36 | 54.3 | 31.3 | -0.05 |
| 2026-10-21 | EOLS | 7.35 | 54.3 | 31.3 | -0.05 |
| 2026-10-22 | EOLS | 7.40 | 54.3 | 30.9 | -0.05 |
| 2026-10-23 | EOLS | 7.00 | 54.3 | 30.9 | -0.05 |
| 2026-10-26 | EOLS | 7.18 | 54.3 | 31.1 | -0.05 |
| 2026-10-27 | EOLS | 7.36 | 54.3 | 31.2 | -0.05 |
| 2026-10-28 | EOLS | 7.64 | 54.3 | 31.6 | -0.05 |
| 2026-10-29 | EOLS | 7.51 | 54.3 | 30.7 | -0.05 |
| 2026-10-30 | EOLS | 7.35 | 54.3 | 30.7 | -0.05 |
| 2026-11-02 | EOLS | 7.16 | 54.3 | 30.6 | -0.05 |
| 2026-11-03 | EOLS | 7.37 | 54.3 | 30.9 | -0.05 |
| 2026-11-04 | EOLS | 7.46 | 54.3 | 31.0 | -0.05 |
| 2026-11-05 | EOLS | 6.80 | 54.3 | 29.9 | -0.05 |
| 2026-11-06 | EOLS | 6.80 | 278.8 | 27.4 | -0.05 |
| 2026-11-09 | EOLS | 6.98 | 278.8 | 27.7 | -0.05 |
| 2026-11-10 | EOLS | 6.81 | 278.8 | 30.2 | -0.05 |
| 2026-11-11 | EOLS | 7.43 | 278.8 | 31.7 | -0.05 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
22 items
«
‹
Current Page1 of 1
›
»
21 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-13 | EOLS | -1.26 | 9.53 | 9.73 |
| 2026-10-14 | EOLS | -1.26 | 9.53 | 9.73 |
| 2026-10-15 | EOLS | -1.26 | 9.53 | 9.73 |
| 2026-10-16 | EOLS | -1.26 | 9.53 | 9.73 |
| 2026-10-19 | EOLS | -1.26 | 9.52 | 9.73 |
| 2026-10-20 | EOLS | -1.26 | 9.52 | 9.73 |
| 2026-10-21 | EOLS | -1.26 | 9.52 | 9.73 |
| 2026-10-22 | EOLS | -1.26 | 9.52 | 9.73 |
| 2026-10-23 | EOLS | -1.26 | 9.52 | 9.73 |
| 2026-10-26 | EOLS | -1.26 | 7.86 | 9.73 |
| 2026-10-27 | EOLS | -1.26 | 7.86 | 11.08 |
| 2026-10-28 | EOLS | -1.26 | 7.86 | 11.08 |
| 2026-10-29 | EOLS | -1.26 | 7.86 | 11.08 |
| 2026-10-30 | EOLS | -1.26 | 7.86 | 11.08 |
| 2026-11-02 | EOLS | -1.26 | 7.73 | 11.08 |
| 2026-11-03 | EOLS | -1.26 | 7.73 | 11.08 |
| 2026-11-05 | EOLS | -1.26 | 7.73 | 11.08 |
| 2026-11-06 | EOLS | -1.26 | 7.73 | 11.08 |
| 2026-11-09 | EOLS | -1.26 | 7.28 | 11.06 |
| 2026-11-10 | EOLS | -1.26 | 7.28 | 11.06 |
| 2026-11-11 | EOLS | -1.26 | 7.28 | 10.39 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
21 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
-0.16
Avg. EPS Est. Current Quarter
0.05
Avg. EPS Est. Next Quarter
Insider Transactions
-1.26
Institutional Transactions
7.28
Beta
1.35
Average Sales Estimate Current Quarter
99
Average Sales Estimate Next Quarter
88
Fair Value
Quality Score
40
Growth Score
47
Sentiment Score
8
Actual DrawDown %
58.3
Max Drawdown 5-Year %
-77.5
Target Price
15.4
P/E
Forward P/E
22.48
PEG
P/S
1.51
P/B
P/Free Cash Flow
EPS
-0.47
Average EPS Est. Cur. Y
-0.05
EPS Next Y. (Est.)
0.29
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
-9.56
Relative Volume
1.36
Return on Equity vs Sector %
55.9
Return on Equity vs Industry %
75.6
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
31.7
◆
EOLS
Healthcare
$7.42
📉
N/A
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
8/20
Pullback
7/25
Volume
3/15
Valuation
13/20
TP/AR
3/10
Options
7/10
RSI
51.3
Range 1M
64.7%
Sup Dist
10.6%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
3/25
Growth
25/30
Estimates
4/20
Inst/Vol
8/15
Options
8/10
EPS Yr
92.6%
EPS NY
1115.4%
52W%
63.7%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+57% upside
Quality
7/30
Valuation
11/30
Growth
18/25
Stability
6/10
LT Trend
2/5
Upside
+57%
Quality
40
Click a card to see score breakdown
Full Analysis →
EOLS — P/E HistoricalDrug Manufacturers - Specialty & Generic
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 365
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
EOLS
Latest News
—
Caricamento notizie per EOLS…
stock quote shares EOLS – Evolent Health Inc. Stock Price stock today
news today EOLS – Evolent Health Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch EOLS – Evolent Health Inc. yahoo finance google finance
stock history EOLS – Evolent Health Inc. invest stock market
stock prices EOLS premarket after hours
ticker EOLS fair value insiders trading